ZA200301852B - A method of analgesia. - Google Patents
A method of analgesia. Download PDFInfo
- Publication number
- ZA200301852B ZA200301852B ZA200301852A ZA200301852A ZA200301852B ZA 200301852 B ZA200301852 B ZA 200301852B ZA 200301852 A ZA200301852 A ZA 200301852A ZA 200301852 A ZA200301852 A ZA 200301852A ZA 200301852 B ZA200301852 B ZA 200301852B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- composition
- pain
- sodium channel
- channel blocking
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 64
- 230000036592 analgesia Effects 0.000 title claims description 9
- 208000002193 Pain Diseases 0.000 claims description 139
- 230000036407 pain Effects 0.000 claims description 104
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims description 97
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims description 94
- 229950010357 tetrodotoxin Drugs 0.000 claims description 91
- 108010052164 Sodium Channels Proteins 0.000 claims description 67
- 102000018674 Sodium Channels Human genes 0.000 claims description 67
- 150000001875 compounds Chemical class 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 58
- 230000000903 blocking effect Effects 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 31
- 241000124008 Mammalia Species 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 208000004296 neuralgia Diseases 0.000 claims description 13
- 208000021722 neuropathic pain Diseases 0.000 claims description 13
- 238000007910 systemic administration Methods 0.000 claims description 13
- -1 ethoxy-tetrodotoxin Chemical compound 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 230000000638 stimulation Effects 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 206010013663 drug dependence Diseases 0.000 claims description 9
- 230000037406 food intake Effects 0.000 claims description 9
- 208000011117 substance-related disease Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 8
- COVOMQKTVSVWBZ-CJCGOCGYSA-N deoxytetrodotoxin Chemical compound O1C(C2(O)CO)(O)OC3C(O)C1[C@@H]1CN=C(N)NC12C3O COVOMQKTVSVWBZ-CJCGOCGYSA-N 0.000 claims description 7
- STNXQECXKDMLJK-UHFFFAOYSA-N (4betaO)-4,9-anhydro-tetrodotoxin Natural products C12C(C3(O)CO)OC4(O)C5OC2N=C(N)NC15C(O)C3O4 STNXQECXKDMLJK-UHFFFAOYSA-N 0.000 claims description 6
- FFOVFIRMBLLEJP-UHFFFAOYSA-N 2,3,4,7-tetrahydro-1h-purine Chemical group N1CNC=C2NC=NC21 FFOVFIRMBLLEJP-UHFFFAOYSA-N 0.000 claims description 6
- STNXQECXKDMLJK-NLWUVLGBSA-N anhydroepitetrodotoxin Chemical compound C12C([C@@]3(O)CO)O[C@@]4(O)[C@H]5OC2N=C(N)N[C@@]15[C@H](O)[C@@H]3O4 STNXQECXKDMLJK-NLWUVLGBSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- RZEZZMTUAUQGFF-UHFFFAOYSA-N tetrodaminotoxin Chemical compound OC1C(C2O)OC3(O)OC2C2C(N)N=C(N)NC21C3(O)CO RZEZZMTUAUQGFF-UHFFFAOYSA-N 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 5
- 208000018084 Bone neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 5
- PPEKGEBBBBNZKS-UHFFFAOYSA-N Neosaxitoxin Natural products N=C1N(O)C(COC(=O)N)C2N=C(N)NC22C(O)(O)CCN21 PPEKGEBBBBNZKS-UHFFFAOYSA-N 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- MWPMJZZQPDXVJT-UHFFFAOYSA-N Tetrodonic acid Natural products N1C(N)=NC2OC(C(O)=O)C31C2C(O)C(O)(CO)C(O)C3O MWPMJZZQPDXVJT-UHFFFAOYSA-N 0.000 claims description 5
- 230000002411 adverse Effects 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 239000000501 collagen implant Substances 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 210000004392 genitalia Anatomy 0.000 claims description 5
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 230000001926 lymphatic effect Effects 0.000 claims description 5
- SVOKHTHBCRETOQ-CNKCMGRGSA-N methoxytetrodotoxin Chemical compound OC1C(C2O)OC3(O)OC2[C@@H]2[C@@H](OC)N=C(N)NC21C3(O)CO SVOKHTHBCRETOQ-CNKCMGRGSA-N 0.000 claims description 5
- PPEKGEBBBBNZKS-HGRQIUPRSA-N neosaxitoxin Chemical compound N=C1N(O)[C@@H](COC(=O)N)[C@@H]2NC(=N)N[C@@]22C(O)(O)CCN21 PPEKGEBBBBNZKS-HGRQIUPRSA-N 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- MWPMJZZQPDXVJT-JTUKEBEQSA-N tetrodonicacid Chemical compound [C@]12([C@H](C(O)=O)O[C@@H]3N=C(N1)N)[C@@H]3[C@@H](O)[C@@](O)(CO)[C@H](O)[C@@H]2O MWPMJZZQPDXVJT-JTUKEBEQSA-N 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000004435 urinary system cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 239000007933 dermal patch Substances 0.000 claims 4
- 239000007972 injectable composition Substances 0.000 claims 4
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 230000007794 irritation Effects 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 230000002441 reversible effect Effects 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000024558 digestive system cancer Diseases 0.000 claims 3
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000007048 respiratory system cancer Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 description 19
- 108091006146 Channels Proteins 0.000 description 15
- 208000005298 acute pain Diseases 0.000 description 14
- 230000006378 damage Effects 0.000 description 13
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 13
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 13
- 239000000730 antalgic agent Substances 0.000 description 12
- 210000001044 sensory neuron Anatomy 0.000 description 11
- 210000003594 spinal ganglia Anatomy 0.000 description 11
- 210000003169 central nervous system Anatomy 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 208000005890 Neuroma Diseases 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 210000000929 nociceptor Anatomy 0.000 description 8
- 108091008700 nociceptors Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000004983 Phantom Limb Diseases 0.000 description 7
- 206010056238 Phantom pain Diseases 0.000 description 7
- 229940035676 analgesics Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003589 local anesthetic agent Substances 0.000 description 7
- 229940005483 opioid analgesics Drugs 0.000 description 7
- 206010058019 Cancer Pain Diseases 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- 208000035154 Hyperesthesia Diseases 0.000 description 6
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 206010064012 Central pain syndrome Diseases 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229960004194 lidocaine Drugs 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229940121367 non-opioid analgesics Drugs 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 5
- 229940127240 opiate Drugs 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 239000003195 sodium channel blocking agent Substances 0.000 description 5
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- USXKBURXVCBLKJ-UHFFFAOYSA-N chiridquitoxin Chemical compound C12C(O)N=C(N)NC2(C2O)C(O)C3C(C(O)C(N)C(O)=O)(O)C1OC2(O)O3 USXKBURXVCBLKJ-UHFFFAOYSA-N 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000000014 opioid analgesic Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 101710134422 Sodium channel protein type 10 subunit alpha Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229960001797 methadone Drugs 0.000 description 3
- 230000007830 nerve conduction Effects 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- CFMYXEVWODSLAX-PZKHIREQSA-N O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@H](O)N=C(N)N1 Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@H](O)N=C(N)N1 CFMYXEVWODSLAX-PZKHIREQSA-N 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960003406 levorphanol Drugs 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 239000003402 opiate agonist Substances 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940125794 sodium channel blocker Drugs 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- LFXVBFTVUBWIQT-UHFFFAOYSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-quinazolin-1-amine Chemical class C1CCCC2N(N)CNCC21 LFXVBFTVUBWIQT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100084990 Caenorhabditis elegans rpn-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010024503 Limb reduction defect Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 101100473185 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rpn-1 gene Proteins 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 241001441723 Takifugu Species 0.000 description 1
- 241001505535 Taricha torosa Species 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000026925 anterograde axon cargo transport Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
- 229940099212 dilaudid Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940072340 dolophine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940089466 nalfon Drugs 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical compound NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000004044 posterior horn cell Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000000238 shellfish toxin Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940078279 trilisate Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Laser Surgery Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001245171A CN1284536C (zh) | 2000-09-18 | 2000-09-18 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301852B true ZA200301852B (en) | 2004-06-21 |
Family
ID=4590472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301852A ZA200301852B (en) | 2000-09-18 | 2003-03-06 | A method of analgesia. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6407088B1 (de) |
| EP (3) | EP2298306B1 (de) |
| JP (1) | JP2004508404A (de) |
| KR (2) | KR100891568B1 (de) |
| CN (1) | CN1284536C (de) |
| AT (2) | ATE542534T1 (de) |
| AU (1) | AU2002213785A1 (de) |
| BG (1) | BG107690A (de) |
| BR (1) | BR0113961A (de) |
| CA (1) | CA2421562C (de) |
| DE (1) | DE60140466D1 (de) |
| EA (1) | EA004870B1 (de) |
| EE (1) | EE200300106A (de) |
| ES (1) | ES2435463T3 (de) |
| HR (1) | HRP20030202A2 (de) |
| HU (1) | HUP0302677A3 (de) |
| IL (1) | IL154342A0 (de) |
| IS (1) | IS6719A (de) |
| MX (1) | MXPA03002389A (de) |
| NO (1) | NO323960B1 (de) |
| PL (1) | PL360616A1 (de) |
| SK (1) | SK3732003A3 (de) |
| UA (1) | UA76960C2 (de) |
| WO (1) | WO2002022129A1 (de) |
| YU (1) | YU17103A (de) |
| ZA (1) | ZA200301852B (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU738197C (en) | 1997-04-22 | 2002-05-16 | Cocensys, Inc. | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| CN1236773C (zh) | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
| US7119062B1 (en) | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
| CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
| CN1203860C (zh) * | 2001-06-22 | 2005-06-01 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
| BR0214126A (pt) * | 2001-11-15 | 2004-10-13 | Micro Algae Corp | Composiçáo farmacêutica para interferir na transmissão neuronal, preparação para o rejuvenescimento facial, e, métodos para interferir na transmissão neuronal, e na contração muscular |
| WO2004013637A1 (en) * | 2002-08-01 | 2004-02-12 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37) |
| EP1589959A2 (de) * | 2003-01-30 | 2005-11-02 | Dynogen Pharmaceuticals Inc. | Verfahren zur behandlung von erkrankungen der unteren harnwege mit natriumkanalmodulatoren |
| CN1568999A (zh) * | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
| JP2005154368A (ja) * | 2003-11-27 | 2005-06-16 | Teikoku Seiyaku Co Ltd | ジソピラミド含有神経因性疼痛の鎮痛剤 |
| CA2607206C (en) * | 2004-05-07 | 2016-06-14 | Phytotox Limited | Transdermal administration of phycotoxins |
| EP1824488B1 (de) * | 2004-05-07 | 2017-08-09 | Algenis SpA | Phycotoxine und verwendungen damit |
| US20050282836A1 (en) * | 2004-06-22 | 2005-12-22 | Weiyang Lin | Solid orally ingestible formulations of tetrodotoxin |
| US20060034823A1 (en) * | 2004-08-13 | 2006-02-16 | Paul Reid | Method of production and use of crotoxin as an analgesic |
| CN100363006C (zh) * | 2004-08-20 | 2008-01-23 | 厦门朝阳生物工程有限公司 | 一种戒毒制剂及其制备方法 |
| WO2006032481A1 (en) * | 2004-09-21 | 2006-03-30 | Laboratorios Del Dr. Esteve S.A. | Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain |
| CN101039675A (zh) * | 2004-09-22 | 2007-09-19 | 埃斯蒂文博士实验室股份有限公司 | 河豚毒素及其衍生物用于治疗外周神经源性神经痛 |
| EP1690541A1 (de) * | 2005-02-11 | 2006-08-16 | Laboratorios Del Dr. Esteve, S.A. | Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit |
| EP1714655A1 (de) * | 2005-04-22 | 2006-10-25 | Laboratorios Del Dr. Esteve, S.A. | Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit |
| EP1853268A1 (de) * | 2005-02-11 | 2007-11-14 | Wex Pharmaceuticals Inc. | Verwendung von natriumkanalblockern und ihrer analoga zur behandlung von nikotin-abhängigkeit |
| EP1702627A1 (de) * | 2005-03-18 | 2006-09-20 | Laboratorios Del Dr. Esteve, S.A. | Analgetische Kombination aus Natriumkanalblocker und Opioid Antagonisten |
| CA2619856A1 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals Inc. | Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
| WO2007025213A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the management of musculoskeletal pain |
| US20070148159A1 (en) * | 2005-12-22 | 2007-06-28 | Reid Paul F | Use of crotoxin as an analgesic - CIP |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| EP1844781A1 (de) | 2006-02-22 | 2007-10-17 | Wex Pharmaceuticals Inc. | Verwendung von Natriumkanalblockern für die Behandlung von vorzeitigen Wehen |
| WO2007110220A1 (en) * | 2006-03-27 | 2007-10-04 | Wex Pharmaceuticals Inc. | USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6 |
| EP1844782A1 (de) * | 2006-03-27 | 2007-10-17 | Wex Pharmaceuticals, Inc | 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen |
| US9018222B2 (en) | 2006-03-27 | 2015-04-28 | Wex Medical Limited | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| EP1844783A1 (de) * | 2006-03-27 | 2007-10-17 | Wex Pharmaceuticals, Inc | 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen |
| CN100438873C (zh) * | 2006-06-26 | 2008-12-03 | 黄致强 | 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用 |
| EP1882692A1 (de) * | 2006-07-28 | 2008-01-30 | Wex Pharmaceuticals Inc. | Dimethano-[1,3]dioxocino[6,5-D]Pyrimidine-Spiro-Derivate von Tetrodotoxin, Verfahren ihrer Herstellung und ihre Verwendung zur Behandlung von Schmerzen |
| US20090042987A1 (en) * | 2007-07-06 | 2009-02-12 | Michael Lionel Selley | Treatment of neuropathic pain |
| CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
| US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
| US20120034296A1 (en) * | 2009-04-08 | 2012-02-09 | Massachusetts Institute Of Technology | Prolonged duration local anesthesia with minimal toxicity |
| CN102811722A (zh) * | 2010-02-10 | 2012-12-05 | 菲特托克斯有限公司 | 用石房蛤毒素衍生物对触觉丧失进行的治疗 |
| EP2646107A2 (de) | 2010-12-01 | 2013-10-09 | Spinal Modulation Inc. | Wirkstofffreisetzungssysteme für selektive nervenmodulation |
| CN105189553A (zh) | 2013-03-14 | 2015-12-23 | 瑞泽恩制药公司 | Nav1.7的人抗体 |
| TR201903411T4 (tr) | 2013-03-15 | 2019-04-22 | Childrens Medical Ct Corp | Uzun süreli lokal anestezi için neosaksitoksin kombinasyon formülasyonları. |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN107198689A (zh) * | 2017-07-11 | 2017-09-26 | 东新皓特（北京）生化科技有限公司 | 用于治疗疼痛病症的河豚毒素药物组合物及外用药 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022899A (en) | 1973-06-12 | 1977-05-10 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
| US4029793A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
| AU1888195A (en) * | 1994-03-17 | 1995-10-03 | Nanning Maple Leaf Pharmaceutical Co. Ltd. | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence |
| CN1072486C (zh) * | 1996-09-24 | 2001-10-10 | 王维国 | 用于戒毒、镇痛的药剂及其制法 |
| US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
| US6326020B1 (en) * | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
| CN1236773C (zh) * | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
| CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
-
2000
- 2000-09-18 CN CNB001245171A patent/CN1284536C/zh not_active Expired - Lifetime
- 2000-10-25 US US09/695,053 patent/US6407088B1/en not_active Expired - Lifetime
-
2001
- 2001-09-11 ES ES10180006T patent/ES2435463T3/es not_active Expired - Lifetime
- 2001-09-11 EE EEP200300106A patent/EE200300106A/xx unknown
- 2001-09-11 DE DE60140466T patent/DE60140466D1/de not_active Expired - Lifetime
- 2001-09-11 EA EA200300172A patent/EA004870B1/ru unknown
- 2001-09-11 EP EP10180006.8A patent/EP2298306B1/de not_active Expired - Lifetime
- 2001-09-11 AT AT04022073T patent/ATE542534T1/de active
- 2001-09-11 YU YU17103A patent/YU17103A/sh unknown
- 2001-09-11 SK SK373-2003A patent/SK3732003A3/sk unknown
- 2001-09-11 BR BR0113961-4A patent/BR0113961A/pt not_active IP Right Cessation
- 2001-09-11 HU HU0302677A patent/HUP0302677A3/hu unknown
- 2001-09-11 AU AU2002213785A patent/AU2002213785A1/en not_active Abandoned
- 2001-09-11 JP JP2002526380A patent/JP2004508404A/ja not_active Abandoned
- 2001-09-11 KR KR1020037003723A patent/KR100891568B1/ko active IP Right Grant
- 2001-09-11 KR KR1020077023825A patent/KR20070112864A/ko not_active Application Discontinuation
- 2001-09-11 CA CA2421562A patent/CA2421562C/en not_active Expired - Lifetime
- 2001-09-11 WO PCT/CN2001/001391 patent/WO2002022129A1/en active Application Filing
- 2001-09-11 EP EP04022073A patent/EP1563839B1/de not_active Expired - Lifetime
- 2001-09-11 IL IL15434201A patent/IL154342A0/xx unknown
- 2001-09-11 PL PL36061601A patent/PL360616A1/xx unknown
- 2001-09-11 AT AT01982091T patent/ATE447959T1/de not_active IP Right Cessation
- 2001-09-11 MX MXPA03002389A patent/MXPA03002389A/es active IP Right Grant
- 2001-09-11 EP EP01982091A patent/EP1320369B1/de not_active Expired - Lifetime
- 2001-11-09 UA UA2003032528A patent/UA76960C2/uk unknown
-
2003
- 2003-02-14 IS IS6719A patent/IS6719A/is unknown
- 2003-02-27 NO NO20030915A patent/NO323960B1/no unknown
- 2003-03-06 ZA ZA200301852A patent/ZA200301852B/en unknown
- 2003-03-17 HR HR20030202A patent/HRP20030202A2/hr not_active Application Discontinuation
- 2003-03-31 BG BG107690A patent/BG107690A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200301852B (en) | A method of analgesia. | |
| Lim | Neuropharmacology of pain and analgesia | |
| EP1007045B1 (de) | Topische anwendung von opioiden wie morphin | |
| Ungerleider et al. | Therapeutic issues of marijuana and THC (tetrahydrocannabinol) | |
| US10278951B1 (en) | Method of treating opiate dependency using tetrahydrocannabinol extracts | |
| CN112569237B (zh) | 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用 | |
| Akuzawa et al. | Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys | |
| CN110279691B (zh) | 一种外科术后护理镇痛药物及其用途 | |
| AU2007200073B2 (en) | A Method of Analgesia | |
| De Conno | Cancer pain relief: A practical manual | |
| Yadav | Pharmacology & Toxicology | |
| US20220218598A1 (en) | Methods and compositions for rapid delivery of anti-seizure therapeutics | |
| CN110237069B (zh) | 一种磷酸二酯酶4抑制剂的应用 | |
| Henry et al. | Ondansetron is effective in treatment of pruritus after intrathecal fantanyl | |
| Nguyen | Kappa opioid signaling in the brainstem and spinal cord for itch and pain | |
| Frajmund | Functional Effects of the Relaxin-3/RXFP-3 Pathway on the Affective Dimension of Chronic Pain | |
| US20090270401A1 (en) | Use of a dihydroimidazopyrazoine derivative for treating or preventing pain | |
| Jaffe | DEFINITIONS AND TERMINOLOGY | |
| Nagesh | Comparative study between epidural Bupivacaine with buprenorphine and epidural bupivacaine for post operative analgesia in abdominal and lower limb surgery | |
| Suresh | Clinical Study of Low Dose Intrathecal Buprenorphine for Post Operative Analgesia | |
| Preethi | Low Dose of Intrathecal Buprenorphine (50µg) for Post-Operative Analgesia–Clinical Study | |
| WO2010120203A1 (ru) | Применение органических красителей в качестве обезболивающих средств | |
| KR20070085036A (ko) | 정신분열성 정신병 치료를 위한 데옥시페가닌의 용도 |